keyword
MENU ▼
Read by QxMD icon Read
search

ustekinumab

keyword
https://www.readbyqxmd.com/read/28926467/a-systematic-review-and-meta-analysis-of-efficacy-and-safety-of-novel-interleukin-inhibitors-in-the-management-of-psoriatic-arthritis
#1
Jawad Bilal, Irbaz Bin Riaz, Muhammad Umar Kamal, Mazen Elyan, Dominick Sudano, Muhammad Asim Khan
OBJECTIVE: The aim of this study was to systemically review the efficacy and safety of inhibitors of interleukin 6 (IL-6): clazakizumab, IL-12/23: ustekinumab, and IL-17A: secukinumab, brodalumab, and ixekizumab in psoriatic arthritis (PsA). METHODS: The literature search was conducted using MEDLINE, EMBASE, Cochrane Library, Scopus, and Web of Science. We included randomized controlled trials that assessed the efficacy of IL inhibitors and reported American College of Rheumatology 20 response at 24 weeks...
September 19, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28921458/pharmacogenetics-and-pharmacogenomics-in-moderate-to-severe-psoriasis
#2
REVIEW
María C Ovejero-Benito, Ester Muñoz-Aceituno, Alejandra Reolid, Miriam Saiz-Rodríguez, Francisco Abad-Santos, Esteban Daudén
Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis...
September 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28899951/lowering-interleukin-12-activity-improves-myocardial-and-vascular-function-compared-with-tumor-necrosis-factor-a-antagonism-or-cyclosporine-in-psoriasis
#3
Ignatios Ikonomidis, Evangelia Papadavid, George Makavos, Ioanna Andreadou, Maria Varoudi, Kostas Gravanis, Kostas Theodoropoulos, George Pavlidis, Helen Triantafyllidi, Paraskevi Moutsatsou, Christina Panagiotou, John Parissis, Efstathios Iliodromitis, John Lekakis, Dimitrios Rigopoulos
BACKGROUND: Interleukin (IL)-12 activity is involved in the pathogenesis of psoriasis and acute coronary syndromes. We investigated the effects of IL-12 inhibition on vascular and left ventricular (LV) function in psoriasis. METHODS AND RESULTS: One hundred fifty psoriasis patients were randomized to receive an anti-IL-12/23 (ustekinumab, n=50), anti-tumor necrosis factor-a (TNF-α; etanercept, n=50), or cyclosporine treatment (n=50). At baseline and 4 months post-treatment, we measured (1) LV global longitudinal strain, twisting, and percent difference between peak twisting and untwisting at mitral valve opening (%untwMVO) using speckle-tracking echocardiography, (2) coronary flow reserve, (3) pulse wave velocity and augmentation index, (4) circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), TNF-α, IL-6, IL-12, IL-17, malondialdehyde, and fetuin-a...
September 2017: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28898541/biologics-combined-with-conventional-systemic-agents-or-phototherapy-for-the-treatment-of-psoriasis-real-life-data-from-psonet-registries
#4
C I Busard, A D Cohen, P Wolf, S Gkalpakiotis, S Cazzaniga, R S Stern, B A Hutten, I Feldhamer, F Quehenberger, R Lichem, M Kojanova, E Adenubiova, A Addis, L Naldi, P I Spuls
BACKGROUND: Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes. OBJECTIVE: To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice. METHODS: We collected data on frequency of use, demographics, treatment characteristics and drug survival of biologics combined with conventional systemic agents or phototherapy in five PSONET registries...
September 12, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28895664/the-severe-and-acute-complications-of-the-biologics-in-psoriasis
#5
Elias Oussedik, Nupur U Patel, Devin R Cash, Angela S Gupta, Steven R Feldman
Biologic therapies have revolutionized the approach to immune-mediated diseases such as psoriasis. Due to their favorable safety profiles and excellent efficacy, biologic agents are considered the gold-standard for moderate-to-severe psoriasis. The aim of this paper is to saliently review the severe and acute complications of the Food and Drug Administration (FDA) approved biologic agents for psoriasis. Reviewed agents include tumor necrosis factor alpha (TNF-alpha) inhibitors (etanercept, infliximab, and adalimumab), interleukin 12/23 inhibitors (ustekinumab), and interleukin 17 inhibitors (secukinumab and ixekizumab)...
September 12, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28894754/natural-modulators-of-endosomal-toll-like-receptor-mediated-psoriatic-skin-inflammation
#6
REVIEW
Chao-Yang Lai, Yu-Wen Su, Kuo-I Lin, Li-Chung Hsu, Tsung-Hsien Chuang
Psoriasis is a chronic inflammatory autoimmune disease that can be initiated by excessive activation of endosomal toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9. Therefore, inhibitors of endosomal TLR activation are being investigated for their ability to treat this disease. The currently approved biological drugs adalimumab, etanercept, infliximab, ustekinumab, ixekizumab, and secukizumab are antibodies against effector cytokines that participate in the initiation and development of psoriasis...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28893407/risk-of-malignancy-with-systemic-psoriasis-treatment-in-the-psoriasis-longitudinal-assessment-registry
#7
David Fiorentino, Vincent Ho, Mark G Lebwohl, Luiz Leite, Lori Hopkins, Claudia Galindo, Kavitha Goyal, Wayne Langholff, Steven Fakharzadeh, Bhaskar Srivastava, Richard G Langley
BACKGROUND: The effect of systemic therapy on malignancy risk among patients with psoriasis is not fully understood. OBJECTIVE: Evaluate the impact of systemic treatment on malignancy risk among patients with psoriasis in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). METHODS: Nested case-control analyses were performed among patients with no history of malignancy. Cases were defined as first malignancy (other than nonmelanoma skin cancer) in the Psoriasis Longitudinal Assessment and Registry, and controls were matched by age, sex, geographic region, and time on registry...
September 8, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28886099/serial-quantiferon-tb-gold-testing-in-patients-with-psoriasis-treated-with-ustekinumab
#8
Chuan-Yu Hsiao, Hsien-Yi Chiu, Ting-Shun Wang, Tsen-Fang Tsai
BACKGROUND: There is increasing concern about the risk of latent tuberculosis infection (LTBI) reactivation during the use of biologics for psoriasis. Although ustekinumab had been documented with low risk of tuberculosis, the long-term follow-up of LTBI as determined by QuantiFERON-TB Gold (QFT-G) testing in patients treated with ustekinumab is limited. OBJECTIVES: This study aims to use serial QFT-G testing as a screening method for detecting LTBI in patients with psoriasis from an intermediate tuberculosis burden country...
2017: PloS One
https://www.readbyqxmd.com/read/28885058/ustekinumab-use-in-crohn-s-disease-a-canadian-tertiary-care-centre-experience
#9
Astrid-Jane Greenup, Greg Rosenfeld, Brian Bressler
OBJECTIVES: Real world data regarding clinical response to ustekinumab in Crohn's disease is lacking. We report our experience of ustekinumab use using a novel subcutaneous (SC) induction strategy and aim to identify predictors of response. MATERIALS AND METHODS: A retrospective, observational study of compassionate ustekinumab use in Crohn's disease was conducted with the use of a standard or high dose SC induction protocol. Symptomatic response was assessed after 3 months (short-term), and if remaining on therapy, within 3-12 months (medium-term) and at least 12 months (long-term)...
September 8, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28870657/use-of-biologic-therapy-by-pregnant-women-with-inflammatory-bowel-disease-does-not-affect-infant-response-to-vaccines
#10
Dawn B Beaulieu, Ashwin N Ananthakrishnan, Christopher Martin, Russell D Cohen, Sunanda V Kane, Uma Mahadevan
BACKGROUND & AIMS: In women with inflammatory bowel diseases (IBD), exposure to immunomodulator or biologic therapy has not been associated with adverse events during pregnancy or outcomes of newborns. We investigated whether exposure of patients to these agents during pregnancy affects serologic responses to vaccines in newborns. METHODS: We collected data from the Pregnancy in IBD and Neonatal Outcomes registry, which records outcomes of pregnant women with diagnosis of IBD receiving care at multiple centers in the United States, from 2007 - 2016...
September 1, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28866870/secondary-syphilis-infection-under-treatment-with-ustekinumab
#11
U Uslu, F Heppt, M Sticherling
No abstract text is available yet for this article.
September 3, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28858074/efficacy-of-combination-vedolizumab-and-ustekinumab-for-refractory-crohn-s-disease
#12
Kayci Huff-Hardy, Mai Bedair, Rebecca Vazquez, Ezra Burstein
No abstract text is available yet for this article.
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28855200/real-world-validation-of-the-minimal-disease-activity-index-in-psoriatic-arthritis-an-analysis-from-a-prospective-observational-biological-treatment-registry
#13
Proton Rahman, Michel Zummer, Louis Bessette, Philip Baer, Boulos Haraoui, Andrew Chow, John Kelsall, Suneil Kapur, Emmanouil Rampakakis, Eliofotisti Psaradellis, Allen J Lehman, Francois Nantel, Brendan Osborne, Cathy Tkaczyk
OBJECTIVE: To describe the minimal disease activity (MDA) rate over time in patients with psoriatic arthritis (PsA) receiving antitumour necrosis factor agents, evaluate prognostic factors of MDA achievement and identify the most common unmet criteria among MDA achievers. DESIGN: Biologic Treatment Registry Across Canada (BioTRAC): ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis, ankylosing spondylitis or PsA with infliximab (IFX), golimumab (GLM) or ustekinumab...
August 30, 2017: BMJ Open
https://www.readbyqxmd.com/read/28838418/ustekinumab-and-anti-interleukin-23-agents-in-crohn-s-disease
#14
REVIEW
Parakkal Deepak, William J Sandborn
This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials...
September 2017: Gastroenterology Clinics of North America
https://www.readbyqxmd.com/read/28836064/treatment-of-severe-psoriasis-in-children-recommendations-of-an-italian-expert-group
#15
Anna Belloni Fortina, Federico Bardazzi, Samantha Berti, Claudia Carnevale, Vito Di Lernia, Maya El Hachem, Iria Neri, Carlo Mario Gelmetti, Viviana Lora, Carlo Mazzatenta, Mirella Milioto, Gaia Moretta, Annalisa Patrizi, Ketty Peris, Alberto Villani
This article provides comprehensive recommendations for the systemic treatment of severe pediatric psoriasis based on evidence obtained from a systematic review of the literature and the consensus opinion of expert dermatologists and pediatricians. For each systemic treatment, the grade of recommendation (A, B, C) based on the treatment's approval by the European Medicines Agency for childhood psoriasis and the experts' opinions is discussed. The grade of recommendation for narrow-band-ultraviolet B phototherapy, cyclosporine, and retinoids is C, while that for methotrexate is C/B...
August 23, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28833973/successful-ustekinumab-treatment-of-noninfectious-uveitis-and-concomitant-severe-psoriatic-arthritis-and-plaque-psoriasis
#16
Cristina Mugheddu, Laura Atzori, Maria Del Piano, Astrid Lappi, Monica Pau, Severino Murgia, Ignazio Zucca, Franco Rongioletti
We report the first successful treatment of noninfectious uveitis with ustekinumab in a patient with severe concomitant psoriasis and psoriatic arthritis who failed to respond to conventional immune suppressants and with contraindications to tumor necrosis factor alpha inhibitors.
August 18, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28833005/ustekinumab-for-severe-atopic-dermatitis-an-important-negative-study
#17
R J Samuel, N J Reynolds
No abstract text is available yet for this article.
August 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28825875/monoclonal-antibodies-inhibiting-il-12-23-and-17-for-the-treatment-of-psoriasis
#18
Caleb Jeon, Sahil Sekhon, Di Yan, Ladan Afifi, Mio Nakamura, Tina Bhutani
Psoriasis is a chronic, inflammatory, immune-mediated skin condition that affects 3 to 4% of the adult U.S. population, characterized by well-demarcated, erythematous plaques with silver scale. Psoriasis is associated with many comorbidities including cardiometabolic disease and can have a negative impact on quality of life. The current armamentarium of psoriasis treatment includes topical therapies, phototherapy, oral immunosuppressive therapies, and biologic agents. Over the past two decades, there has been rapid development of novel biologic therapies for the treatment of moderate-to-severe plaque psoriasis...
August 21, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28791450/relative-efficacy-and-safety-of-apremilast-secukinumab-and-ustekinumab-for-the-treatment-of-psoriatic-arthritis
#19
G G Song, Y H Lee
OBJECTIVE: To assess the relative efficacy and safety of apremilast, secukinumab, and ustekinumab at different doses in patients with active psoriatic arthritis (PsA). METHOD: A Bayesian network meta-analysis was conducted, which included randomized controlled trials (RCTs) that examined the efficacy and safety of apremilast 20 mg, apremilast 30 mg, secukinumab 75 mg, secukinumab 150 mg, secukinumab 300 mg, ustekinumab 45 mg, and ustekinumab 90 mg compared with placebo...
August 8, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28789582/long-term-drug-survival-and-predictor-analysis-of-the-whole-psoriatic-patient-population-on-biological-therapy-in-hungary
#20
Lilla Pogácsás, András Borsi, Péter Takács, Éva Remenyik, Lajos Kemény, Sarolta Kárpáti, Péter Holló, Norbert Wikonkál, Rolland Gyulai, Zsuzsanna Károlyi, Pál Rakonczai, Tamás Balázs, Andrea Szegedi
Persistence is an important component of therapeutic success, which depends on a variety of factors. Persistence measured under optimal conditions during clinical trials does not necessarily coincide with persistence observed in the real-world settings. The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a retrospective analysis...
August 9, 2017: Journal of Dermatological Treatment
keyword
keyword
34739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"